Science:Life Sciences
In 2022, investment in biopharmaceutical companies, pipeline activity, and the launch of novel medicines all dropped from the previous year. A new report from IQVIA’s Institute for Human Data Sciences argues the downturn, after two record-setting years, is a post pandemic return to longer-term trends. We spoke to Murray Aitken, executive director of the IQVIA Institute for Human Data Science, about what happened to the biopharmaceutical sector in 2022, how to make sense of the data, and the shifting landscape in therapeutic and geographic investments.
More Episodes
Making A Social Contract That’s Enforceable
2020-03-12
2020-03-12
Fishing for New Drugs
2020-02-27
2020-02-27
Quantifying Neurodegeneration with Precision
2020-01-30
2020-01-30
Reversing Disease Signals
2020-01-16
2020-01-16
Turning Cold Tumors Hot
2020-01-09
2020-01-09
An Effort to Eradicate Preventable Blindness
2019-12-20
2019-12-20
Seeking Success Where Others Have Failed
2019-12-19
2019-12-19
Improving Health with Better Data
2019-12-05
2019-12-05
Get this podcast on your
phone, FREE
